- The FDA accepts for review Bristol-Myers Squibb's (BMY +1.6%) supplemental Biologics License Application (sBLA) seeking approval for the use of Yervoy (ipilimumab) as adjuvant treatment for patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. The PDUFA date is October 28.
- Patients in this category ave a poor prognosis. Once the cancer returns, the survival rates are only 11 - 20%.
- Yervoy is currently cleared for the treatment of adults with metastatic or unresectable melanoma.
- Ipilimumab is a human monoclonal antibody that blocks the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), a protein receptor that downregulates the immune system.
FDA accepts Bristol-Myers' application for expanded use of Yervoy
Recommended For You
About BMY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BMY | - | - |
Bristol-Myers Squibb Company |